TTrialPathMatch Me to Trials
← Back to trials
RecruitingNon Small Cell Lung CancerNon Small Cell Lung Cancer MetastaticNon-small Cell Carcinoma

A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)

Eligible age

18+ yrs

Accepts

All genders

Locations

4 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is to see whether adding liver stereotactic ablative radiotherapy/L-SABR to standard drug therapy is better than standard drug therapy alone for people with metastatic non-small cell lung cancer/NSCLC.

Sponsor: Memorial Sloan Kettering Cancer Center

You may qualify if…

  • ✓ Be greater than 18 years of age on day of signing informed consent.
  • ✓ Have a histologically confirmed diagnosis of stage IV NSCLC (includes patients who have progressed on durvalumab for Stage III NSCLC) without known mutations in (EGFR) or BRAF or rearrangements in ALK (anaplastic lymphoma kinase) or ROS-1.
  • ✓ o Patients with recurrent metastatic NSCLC following prior durvalumab for stage III disease are eligible provided this is their first immunotherapy course for metastatic disease (i.e., the planned anti-PD-(L)1-based regimen represents first-line systemic therapy in the metastatic setting).
  • ✓ Newly diagnosed metastatic non-small cell lung cancer (NSCLC), including both de novo and secondary metastatic disease, with one or more liver metastases
  • ✓ Plan to initiate standard of care anti-PD-(L)1 based immunotherapy +/- platinum based chemotherapy for at least 3 cycles
  • ✓ o Regimens combining anti-CTLA-4 immunotherapy with anti-PD-1 (e.g., ipilimumab plus nivolumab) or anti-PD-L1 (e.g., tremelimumab plus durvalumab) immunotherapy are allowed.
  • ✓ Have a performance status of 0-2 on the ECOG Performance Scale.
  • ✓ Liver function tests:

You may not qualify if…

  • ✕ Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen should be included.
  • ✕ Patients with prior external beam radiation therapy to the liver.
  • ✕ Patients with known active Hepatitis B or Hepatitis C.
  • ✕ Patients with immunosuppression including pharmacological immunosuppression with chronic steroids or immune modulators like cyclosporin or methotrexate and patients with active autoimmune disease.
  • ✕ Patients who are pregnant or breastfeeding
  • ✕ Men or women not using effective contraception.

Where it's recruiting

Florida

Miami

New Jersey

Basking Ridge · Middletown · Montvale

New York

Commack · Harrison · New York · Rockville Centre

Pennsylvania

Allentown

Source: ClinicalTrials.gov · NCT05657873 · last updated 2026-05-07

A Study of Targeted Radiation Therapy in People With Non-Small Cell Lu · TrialPath